CA2480223C - A composition for treating gastric ulcer and a process for preparing the same - Google Patents
A composition for treating gastric ulcer and a process for preparing the same Download PDFInfo
- Publication number
- CA2480223C CA2480223C CA2480223A CA2480223A CA2480223C CA 2480223 C CA2480223 C CA 2480223C CA 2480223 A CA2480223 A CA 2480223A CA 2480223 A CA2480223 A CA 2480223A CA 2480223 C CA2480223 C CA 2480223C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- extract
- ulcer
- plant part
- omeprazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer, amethod for preparing said synergistic herbal composition and a process for the treatment of gastric ulcerusing said composition and more particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model.
Description
A COMPOSITION FOR TREATING GASTRIC ULCER AND A
PROCESS FOR PREPARING THE SAME
Technical Field The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. The present invention also relates to a method for the preparation of the composition. The present invention further relates to a process for the treatment of gastric ulcer using the composition.
Background Art Various theories have been proposed with respect to a cause of ulcer in human.
In particular, it has been elucidated that stress, taking of non-steroidal anti-inflammatory drugs for curing rheumatic diseases, and the like are closely related to ulcer formation, mainly due to relatively excess gastric or duodenal acid secretion. Accordingly it is important to suppress the acid secretion in order to prevent ulcer formation and to cure it.
On the other hand it has been considered that Helicobacter pylori, which is a rod normally existing in stomach, generates ammonia due to its strong urease activity, thereby inducing ulcer. Since it persistently lives within mucus and mucosa, it becomes the greatest cause for recurrence of ulcer. Accordingly, it has been considered that the recurrence of ulcer can be prevented if this bacterium is sterilized.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p1287, published by Popular Prakashan Pvt. Ltd., Mumbai and K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p 608 published by Bishen Singh Mahendrapal Singh, Dehradun for the medicinal properties of Blechnum orintale.
A reference may be made to P.K. Warner in Indian Medicinal Plants- A
compendium of 500 species (1994-1996) Vol. 5, p 396, and The wealth of India (1950-1980), Vol.10 p.
556 published by Council of Scientific and Industrial Research for the various medicinal properties of Vitis vinifera.
A reference may be made to K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.2, p. 80, published by Department of Pharmacognosy, University of Kerala, Trivandrum and The Wealth of India (1950-1980) Vol. 1, p. 34, published by Council of Scientific and Industrial Research for the various medicinal properties of Aegle marmelos.
PROCESS FOR PREPARING THE SAME
Technical Field The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. The present invention also relates to a method for the preparation of the composition. The present invention further relates to a process for the treatment of gastric ulcer using the composition.
Background Art Various theories have been proposed with respect to a cause of ulcer in human.
In particular, it has been elucidated that stress, taking of non-steroidal anti-inflammatory drugs for curing rheumatic diseases, and the like are closely related to ulcer formation, mainly due to relatively excess gastric or duodenal acid secretion. Accordingly it is important to suppress the acid secretion in order to prevent ulcer formation and to cure it.
On the other hand it has been considered that Helicobacter pylori, which is a rod normally existing in stomach, generates ammonia due to its strong urease activity, thereby inducing ulcer. Since it persistently lives within mucus and mucosa, it becomes the greatest cause for recurrence of ulcer. Accordingly, it has been considered that the recurrence of ulcer can be prevented if this bacterium is sterilized.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p1287, published by Popular Prakashan Pvt. Ltd., Mumbai and K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p 608 published by Bishen Singh Mahendrapal Singh, Dehradun for the medicinal properties of Blechnum orintale.
A reference may be made to P.K. Warner in Indian Medicinal Plants- A
compendium of 500 species (1994-1996) Vol. 5, p 396, and The wealth of India (1950-1980), Vol.10 p.
556 published by Council of Scientific and Industrial Research for the various medicinal properties of Vitis vinifera.
A reference may be made to K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.2, p. 80, published by Department of Pharmacognosy, University of Kerala, Trivandrum and The Wealth of India (1950-1980) Vol. 1, p. 34, published by Council of Scientific and Industrial Research for the various medicinal properties of Aegle marmelos.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p.
1239-94, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p 1776 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 5, p 409; K. Narayana Iyer and M. Kolainmal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.8, p. 34, published by Department of Pharmacognosy, University of Kerala, Trivandrum, The Wealth of India (1950-1980) Vol. 10, p. 585, published by Council of Scientific and Industrial Research and S.S. Handa in Indian Herbal Pharmacopoeia (1998), Vol. 1, p.171, published by Regional Research Laboratory, Jammu and IDMA, Mumbai for the various medicinal properties of Withania somnifra.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p 536, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p 997 published by Bishen Singh Mahendrapal Singh, Dehradun;
P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol.
1, p.
1239-94, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p 1776 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 5, p 409; K. Narayana Iyer and M. Kolainmal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.8, p. 34, published by Department of Pharmacognosy, University of Kerala, Trivandrum, The Wealth of India (1950-1980) Vol. 10, p. 585, published by Council of Scientific and Industrial Research and S.S. Handa in Indian Herbal Pharmacopoeia (1998), Vol. 1, p.171, published by Regional Research Laboratory, Jammu and IDMA, Mumbai for the various medicinal properties of Withania somnifra.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p 536, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p 997 published by Bishen Singh Mahendrapal Singh, Dehradun;
P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol.
3, p. 327-29, and The Wealth of India (1950-1980) Vol. 4, p. 19, published by Council of Scientific and Industrial Research of the various medicinal properties of Feronia elephantum.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p1031, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warner in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 4, p 396, and in Illustrated manual of herbal drugs used in Ayurveda (1996) by Y.K.Sarin p.218 for the various medicinal properties of Punica grantum.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p1309, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p 2436 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 5, p. 431, published by orient Longman, Chennai, and The Ayurvedic Pharmacopoeia of India (1986), Vol. 1, p. 104, published by Ministry of Health and Family Welfare, India for the various medicinal properties of Ziniber officnale.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p.
478, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 2, p. 368, published by orient Longman, Chennai; Medicinal plants of India (1987) by G.V. Satyavati Vol. 2 p.429 published by Indian Council of Medical Research; The Wealth of India (1950-1980) Vol.
a 8, p. 98, published by Council of Scientific and Industrial Research, and Y.K.
Sarin in Illustrated manual of herbal drugs used in Ayurveda (1996), p. 268 for the various medicinal properties of Piper nigrum.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p.
966, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warner in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 4, p. 290, published by orient Longman, Chennai; K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.9, p. 49, published by Department of Pharmacognosy, University of Kerala, Trivandrum, and The Wealth of India (1950-1980) Vol. 8, p. 98, published by Council of Scientific and Industrial Research for the various medicinal properties of Piper longum.
A reference may be made to K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p536-540 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 1, p. 203-5, published by orient Longman, and K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.3, p. 23, published by Department of Pharmacognosy, University of Kerala, Trivandrum for the various medicinal properties of Azadirachta indica.
The composition of the present invention should not be treated as an obvious one as none of the citations are able to provide all the advantages of the present invention. .
Summary of the Invention The present invention provides a novel synergistic herbal composition for the treatment of gastric ulcer. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. Also, the present invention provides a process for the preparation of the composition. The present invention further provides a method for the treatment of gastric ulcer using said composition.
3a The present invention provides a herbal composition for the prevention or treatment of a gastric ulcer, said composition comprising: 4-10% by wt. of an extract from a plant part of Aegle marmelos; 4-11% by wt. of an extract from a plant part of Withania somnifra; 5-8% by wt. of an extract from a plant part of Blechnum orintale; 5-11% by wt. of an extract from a plant part of Vitis vinifera; 5-9% by wt. of an extract from a plant part of Feronia elephantum; 8-11 % by wt. of an extract from a plant part of Punica grantum; 4-9% by wt. of an extract from a plant part of Ziniber officnale; 2-11% by wt. of an extract from a plant part of Piper nigrum; 8-12% by wt. of an extract from a plant part of Piper longum; and 2-11% by wt. of an extract from a plant part of Azadirachta indica. In an embodiment, the composition may further comprise one or more pharmaceutically acceptable additives/carriers.
In another aspect, the present invention provides a process for the preparation of a herbal composition for the prevention or treatment of a gastric ulcer, the process comprising: obtaining 4-10% by wt. of an extract from a plant part of Aegle marmelos, 4-11% by wt. of an extract from a plant part of Withania somnifra, 5-8% by wt.
of an extract from a plant part of Blechnum orintale, 5-11 % by wt. of an extract from a plant part of Vitis vinifera, 5-9% by wt. of an extract from a plant part of Feronia elephantum, 8-11% by wt. of an extract from a plant part of Punica grantum, 4-9% by wt. of an extract from a plant part of Ziniber officnale, 2-11% by wt. of an extract from a plant part of Piper nigrum, 8-12% by wt. of an extract from a plant part of Piper longum and 2-11 % by wt. of an extract from a plant part of Azadirachta indica; and mixing the extracts. In an embodiment, the extracts may be mixed with one or more pharmaceutically acceptable additives/carriers.
In another aspect, the present invention provides use of the herbal composition as defined anywhere throughout the entire specification for the prevention or treatment of a gastric ulcer in a subject. In a further aspect, the use may be for the manufacture of a medicament for such prevention or treatment.
Detailed Description of the present Invention In accordance with one aspect of the present invention, there is provided a novel synergistic herbal composition for the treatment of gastric ulcer, said composition comprises an extract essentially obtained from one or more parts of Aegle marmelos and Withania somnifra and optionally from one or more parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper longum and Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
More particularly, the present invention provides a novel synergistic herbal composition for the treatment of gastric ulcer, said composition essentially comprises 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt.
of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, the extract is an aqueous extract.
In another embodiment of the present invention, the plant part of Aegle marrelos, Withania somnifra and Blechnum orintale is root.
In still another embodiment of the present invention, the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit.
In yet another embodiment of the present invention, the plant part of Punica grantum is fruit rind.
In one more embodiment of the present invention, the plant part of Ziniber officnale is rhizome.
In one another embodiment of the present invention, the plant part of Azadirachta indica is bark.
In accordance with another aspect of the present invention, there is provided a process for the preparation of the novel synergistic herbal composition for the treatment of gastric ulcer, said process comprising obtaining an extract essentially from one or more parts of Aegle marmelos and Withania soma f a and optionally from one or more parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigruin, Piper longum and Azadirachta indica and mixing them with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, said process extract is obtained by grinding 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania sonnia and optionally 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia 5 elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica to a fine paste and mixing them with one or more pharmaceutically acceptable additives/carriers.
In another embodiment of the present invention, the extract is an aqueous extract.
In still another embodiment of the present invention, the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
In yet another embodiment of the present invention, the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit.
In one more embodiment of the present invention, the plant part of Punica grantum is fruit rind.
In one another embodiment of the present invention, the plant part of Ziniber officnale is rhizome.
In an embodiment of the present invention, the plant part of Azadirachta indica is bark.
In accordance with a further aspect of the present invention, there is provided a method of treating gastric ulcer in a subject, said method comprises administering an effective amount of the synergistic herbal composition essentially comprising 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11%
by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11%
by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, the subject is a mammal including a human being.
In another embodiment of the present invention, 50 to 100mg of the composition is administered per Kg of body weight to the subject.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p1031, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warner in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 4, p 396, and in Illustrated manual of herbal drugs used in Ayurveda (1996) by Y.K.Sarin p.218 for the various medicinal properties of Punica grantum.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p1309, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p 2436 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 5, p. 431, published by orient Longman, Chennai, and The Ayurvedic Pharmacopoeia of India (1986), Vol. 1, p. 104, published by Ministry of Health and Family Welfare, India for the various medicinal properties of Ziniber officnale.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p.
478, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 2, p. 368, published by orient Longman, Chennai; Medicinal plants of India (1987) by G.V. Satyavati Vol. 2 p.429 published by Indian Council of Medical Research; The Wealth of India (1950-1980) Vol.
a 8, p. 98, published by Council of Scientific and Industrial Research, and Y.K.
Sarin in Illustrated manual of herbal drugs used in Ayurveda (1996), p. 268 for the various medicinal properties of Piper nigrum.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol.
1, p.
966, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warner in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 4, p. 290, published by orient Longman, Chennai; K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.9, p. 49, published by Department of Pharmacognosy, University of Kerala, Trivandrum, and The Wealth of India (1950-1980) Vol. 8, p. 98, published by Council of Scientific and Industrial Research for the various medicinal properties of Piper longum.
A reference may be made to K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p536-540 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 1, p. 203-5, published by orient Longman, and K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Vol.3, p. 23, published by Department of Pharmacognosy, University of Kerala, Trivandrum for the various medicinal properties of Azadirachta indica.
The composition of the present invention should not be treated as an obvious one as none of the citations are able to provide all the advantages of the present invention. .
Summary of the Invention The present invention provides a novel synergistic herbal composition for the treatment of gastric ulcer. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. Also, the present invention provides a process for the preparation of the composition. The present invention further provides a method for the treatment of gastric ulcer using said composition.
3a The present invention provides a herbal composition for the prevention or treatment of a gastric ulcer, said composition comprising: 4-10% by wt. of an extract from a plant part of Aegle marmelos; 4-11% by wt. of an extract from a plant part of Withania somnifra; 5-8% by wt. of an extract from a plant part of Blechnum orintale; 5-11% by wt. of an extract from a plant part of Vitis vinifera; 5-9% by wt. of an extract from a plant part of Feronia elephantum; 8-11 % by wt. of an extract from a plant part of Punica grantum; 4-9% by wt. of an extract from a plant part of Ziniber officnale; 2-11% by wt. of an extract from a plant part of Piper nigrum; 8-12% by wt. of an extract from a plant part of Piper longum; and 2-11% by wt. of an extract from a plant part of Azadirachta indica. In an embodiment, the composition may further comprise one or more pharmaceutically acceptable additives/carriers.
In another aspect, the present invention provides a process for the preparation of a herbal composition for the prevention or treatment of a gastric ulcer, the process comprising: obtaining 4-10% by wt. of an extract from a plant part of Aegle marmelos, 4-11% by wt. of an extract from a plant part of Withania somnifra, 5-8% by wt.
of an extract from a plant part of Blechnum orintale, 5-11 % by wt. of an extract from a plant part of Vitis vinifera, 5-9% by wt. of an extract from a plant part of Feronia elephantum, 8-11% by wt. of an extract from a plant part of Punica grantum, 4-9% by wt. of an extract from a plant part of Ziniber officnale, 2-11% by wt. of an extract from a plant part of Piper nigrum, 8-12% by wt. of an extract from a plant part of Piper longum and 2-11 % by wt. of an extract from a plant part of Azadirachta indica; and mixing the extracts. In an embodiment, the extracts may be mixed with one or more pharmaceutically acceptable additives/carriers.
In another aspect, the present invention provides use of the herbal composition as defined anywhere throughout the entire specification for the prevention or treatment of a gastric ulcer in a subject. In a further aspect, the use may be for the manufacture of a medicament for such prevention or treatment.
Detailed Description of the present Invention In accordance with one aspect of the present invention, there is provided a novel synergistic herbal composition for the treatment of gastric ulcer, said composition comprises an extract essentially obtained from one or more parts of Aegle marmelos and Withania somnifra and optionally from one or more parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper longum and Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
More particularly, the present invention provides a novel synergistic herbal composition for the treatment of gastric ulcer, said composition essentially comprises 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt.
of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, the extract is an aqueous extract.
In another embodiment of the present invention, the plant part of Aegle marrelos, Withania somnifra and Blechnum orintale is root.
In still another embodiment of the present invention, the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit.
In yet another embodiment of the present invention, the plant part of Punica grantum is fruit rind.
In one more embodiment of the present invention, the plant part of Ziniber officnale is rhizome.
In one another embodiment of the present invention, the plant part of Azadirachta indica is bark.
In accordance with another aspect of the present invention, there is provided a process for the preparation of the novel synergistic herbal composition for the treatment of gastric ulcer, said process comprising obtaining an extract essentially from one or more parts of Aegle marmelos and Withania soma f a and optionally from one or more parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigruin, Piper longum and Azadirachta indica and mixing them with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, said process extract is obtained by grinding 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania sonnia and optionally 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia 5 elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica to a fine paste and mixing them with one or more pharmaceutically acceptable additives/carriers.
In another embodiment of the present invention, the extract is an aqueous extract.
In still another embodiment of the present invention, the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
In yet another embodiment of the present invention, the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit.
In one more embodiment of the present invention, the plant part of Punica grantum is fruit rind.
In one another embodiment of the present invention, the plant part of Ziniber officnale is rhizome.
In an embodiment of the present invention, the plant part of Azadirachta indica is bark.
In accordance with a further aspect of the present invention, there is provided a method of treating gastric ulcer in a subject, said method comprises administering an effective amount of the synergistic herbal composition essentially comprising 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11%
by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11%
by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, the subject is a mammal including a human being.
In another embodiment of the present invention, 50 to 100mg of the composition is administered per Kg of body weight to the subject.
In yet another embodiment of the present invention, the composition can be in the form of tablets, capsules, syrup or by any other form known in the art.
In still another embodiment of the present invention, the composition is administered orally, intra-muscularly, and by any other conventional methods.
In one more embodiment of the present invention, the composition may be used for therapeutic as well as prophylactic treatment of gastric ulcer.
In one another embodiment of the present invention, the subject may be administered a single bolus dose or a multiple dose.
Brief Description of the Tables In the tables accompanying the specification, Table 1 represents the effect of Omeprazole (a standard drug) and the new herbal composition (HF) against Cold Restraint Ulcer (CRU) Model.
Table 2 compares the percentage protection of Omeprazole and the Herbal composition (HF) against Cold Restraint Ulcer (CRU) Model.
Table 3 gives the effect of Omeprazole and the Herbal composition (HF) against Aspirin induced ulcer model.
Table 4 gives the percentage protection of Omeprazole and the Herbal composition (HF) against aspirin induced ulcer model.
Table 5 gives the effect of Omeprazole and the Herbal composition (HF) against histamine induced duodenal ulcer in Guinea pig.
Table 6 gives the percentage protection of Omeprazole and the Herbal composition (HF) against histamine induced duodenal ulcer in Guinea pigs.
Table 7 gives the effect of Omeprazole and the Herbal composition (HF) against Ethanol Induced Ulcer Model.
Table 8 gives the percentage protection of Omeprazole and the Herbal composition (HF) against Alcohol induced Ulcer Model.
Table 9 gives the effect of Omeprazole and the Herbal composition (HF) against pyloric ligation induced Ulcer.
Table 10 gives the percentage protection of Omeprazole and the Herbal composition (HF) against pyloric ligation induced Ulcer.
Table 11 gives the composition of the Herbal composition (HF) of the present invention.
The present invention is further described with reference to the following experiments which are given by way of illustration and therefore should not be construed to limit the scope of the invention in any manner.
In still another embodiment of the present invention, the composition is administered orally, intra-muscularly, and by any other conventional methods.
In one more embodiment of the present invention, the composition may be used for therapeutic as well as prophylactic treatment of gastric ulcer.
In one another embodiment of the present invention, the subject may be administered a single bolus dose or a multiple dose.
Brief Description of the Tables In the tables accompanying the specification, Table 1 represents the effect of Omeprazole (a standard drug) and the new herbal composition (HF) against Cold Restraint Ulcer (CRU) Model.
Table 2 compares the percentage protection of Omeprazole and the Herbal composition (HF) against Cold Restraint Ulcer (CRU) Model.
Table 3 gives the effect of Omeprazole and the Herbal composition (HF) against Aspirin induced ulcer model.
Table 4 gives the percentage protection of Omeprazole and the Herbal composition (HF) against aspirin induced ulcer model.
Table 5 gives the effect of Omeprazole and the Herbal composition (HF) against histamine induced duodenal ulcer in Guinea pig.
Table 6 gives the percentage protection of Omeprazole and the Herbal composition (HF) against histamine induced duodenal ulcer in Guinea pigs.
Table 7 gives the effect of Omeprazole and the Herbal composition (HF) against Ethanol Induced Ulcer Model.
Table 8 gives the percentage protection of Omeprazole and the Herbal composition (HF) against Alcohol induced Ulcer Model.
Table 9 gives the effect of Omeprazole and the Herbal composition (HF) against pyloric ligation induced Ulcer.
Table 10 gives the percentage protection of Omeprazole and the Herbal composition (HF) against pyloric ligation induced Ulcer.
Table 11 gives the composition of the Herbal composition (HF) of the present invention.
The present invention is further described with reference to the following experiments which are given by way of illustration and therefore should not be construed to limit the scope of the invention in any manner.
Experimental protocol:
Invivo experiments:
The Applicants have carried out several experiments under different induced ulcer conditions and the effect of the herbal composition were studied and are tabulated herebelow. The effect of the herbal composition has been compared with respect to a known anti-ulcer drug "Omeprazole".
EXPERIMENT 1: EFFECT ON COLD RESTRAINT ULCERS (CRU) MODEL
METHOD: Adult rats of either sex, weighing 150-175 grams are fasted for 24 hours in metallic cages with raised mesh bottoms to prevent coprophagia and were allowed free access to water. The test drugs were administered 45 minutes before immobilizing the animals. The rats were immobilized in the restraint cage and kept at 4 C in BOD incubator for 2 hours (According to the method of Senay and Levine 1967). The animals were sacrificed immediately after the restraint period. The abdomen was cut opened;
stomach was taken out and incised along the greater curvature to observe the gastric lesions with the help of Magnascope (5X magnification) The following arbitrary scoring system was used to grade the severity and intensity of the lesions:
1. Shedding of epithelium = 10 2. Petechial and frank hemorrhages = 20 3. One or two ulcers = 30 4. More than two ulcers = 40 5. Perforated ulcers = 50 The presence of any of these lesions was considered as a positive ulcerogenic response which has been shown as percentage of rats showing gastric lesions. The severity of ulcers is expressed in terms of ulcer index, which is the mean score of gastric lesions of all the rats in a group. The term Ulcer Index is defined as:
Ulcer Index (U.I.) = Us + Up x 10"1 where Us = Mean severity of ulcer score and Up = Percentage of animals with Ulcer incidences The percentage protection is calculated as follows:
Percentage protection = (C-T/C) x 100.
where C= Number of animals showing ulcer response in control group and T= Number of animals showing ulcer response in test group.
Invivo experiments:
The Applicants have carried out several experiments under different induced ulcer conditions and the effect of the herbal composition were studied and are tabulated herebelow. The effect of the herbal composition has been compared with respect to a known anti-ulcer drug "Omeprazole".
EXPERIMENT 1: EFFECT ON COLD RESTRAINT ULCERS (CRU) MODEL
METHOD: Adult rats of either sex, weighing 150-175 grams are fasted for 24 hours in metallic cages with raised mesh bottoms to prevent coprophagia and were allowed free access to water. The test drugs were administered 45 minutes before immobilizing the animals. The rats were immobilized in the restraint cage and kept at 4 C in BOD incubator for 2 hours (According to the method of Senay and Levine 1967). The animals were sacrificed immediately after the restraint period. The abdomen was cut opened;
stomach was taken out and incised along the greater curvature to observe the gastric lesions with the help of Magnascope (5X magnification) The following arbitrary scoring system was used to grade the severity and intensity of the lesions:
1. Shedding of epithelium = 10 2. Petechial and frank hemorrhages = 20 3. One or two ulcers = 30 4. More than two ulcers = 40 5. Perforated ulcers = 50 The presence of any of these lesions was considered as a positive ulcerogenic response which has been shown as percentage of rats showing gastric lesions. The severity of ulcers is expressed in terms of ulcer index, which is the mean score of gastric lesions of all the rats in a group. The term Ulcer Index is defined as:
Ulcer Index (U.I.) = Us + Up x 10"1 where Us = Mean severity of ulcer score and Up = Percentage of animals with Ulcer incidences The percentage protection is calculated as follows:
Percentage protection = (C-T/C) x 100.
where C= Number of animals showing ulcer response in control group and T= Number of animals showing ulcer response in test group.
The effect of the herbal composition of the present invention hereafter referred to as "HF"
against Cold Restraint Ulcer Model (CRU) is given in Table 1. The effect of the standard drug "Omeprazole" is also given in Table 1 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against CRU model are tabulated in Table 2 given at the end of the description.
INFERENCE: The composition of the present invention is significantly effective in CRU
model.
EXPERIMENT 2: EFFECT ON ASPIRIN INDUCED GASTRIC ULCER MODEL
Method: Gastric ulceration was induced by aspirin according to the method of Djahanguiri (1969). Aspirin (150 mg/Kg.) was administered per orally as a suspension in gum-acacia and the animal was sacrificed 5 hr. after the aspirin treatment and the ulcer index with protection index were calculated.
The effect of HF against aspirin induced gastric ulcer is given in Table 3.
The effect of the standard drug "Omeprazole" is also given in Table 3 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against this model are tabulated in Table 4 given at the end of the description.
INFERENCE: The herbal composition of the present invention is effective against Aspirin induced gastric ulcer model.
EXPERIMENT 3: EFFECT ON HISTAMINE INDUCED ULCER MODEL
Method:
1. Animals were fasted for 24 hours with access to water.
2. The drug was given orally 1 hour prior to the histamine administration.
3. Histamine was administered in a dose of 0.25 mg/Kg, i.m. at 30 minutes interval for 7 times and it induced 100 % duodenal ulceration in guinea pig (According to the method of Watt and Eagleton 1964).
4. The animals were sacrificed after half an hour of last injection under ether anesthesia.
5. The stomach along with duodenum were removed washed thoroughly and examined for the lesions. Ulcer index and protection index were calculated.
The effect of HF against Histamine induced duodenal ulcer is given in Table 5.
The effect of the standard drug "Omeprazole" is also given in Table 5 given at the end of the description.
against Cold Restraint Ulcer Model (CRU) is given in Table 1. The effect of the standard drug "Omeprazole" is also given in Table 1 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against CRU model are tabulated in Table 2 given at the end of the description.
INFERENCE: The composition of the present invention is significantly effective in CRU
model.
EXPERIMENT 2: EFFECT ON ASPIRIN INDUCED GASTRIC ULCER MODEL
Method: Gastric ulceration was induced by aspirin according to the method of Djahanguiri (1969). Aspirin (150 mg/Kg.) was administered per orally as a suspension in gum-acacia and the animal was sacrificed 5 hr. after the aspirin treatment and the ulcer index with protection index were calculated.
The effect of HF against aspirin induced gastric ulcer is given in Table 3.
The effect of the standard drug "Omeprazole" is also given in Table 3 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against this model are tabulated in Table 4 given at the end of the description.
INFERENCE: The herbal composition of the present invention is effective against Aspirin induced gastric ulcer model.
EXPERIMENT 3: EFFECT ON HISTAMINE INDUCED ULCER MODEL
Method:
1. Animals were fasted for 24 hours with access to water.
2. The drug was given orally 1 hour prior to the histamine administration.
3. Histamine was administered in a dose of 0.25 mg/Kg, i.m. at 30 minutes interval for 7 times and it induced 100 % duodenal ulceration in guinea pig (According to the method of Watt and Eagleton 1964).
4. The animals were sacrificed after half an hour of last injection under ether anesthesia.
5. The stomach along with duodenum were removed washed thoroughly and examined for the lesions. Ulcer index and protection index were calculated.
The effect of HF against Histamine induced duodenal ulcer is given in Table 5.
The effect of the standard drug "Omeprazole" is also given in Table 5 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against Histamine induced duodenal ulcer are tabulated in Table 6 given at the end of the description.
INFERENCE: The Herbal composition of the present invention "HF" shows significant anti ulcer effect against this model.
EXPERIMENT 4: EFFECT ON ALCOHOL INDUCED GASTRIC ULCERS IN
RATS
Method:
1. Adult rats of either sex were taken; weighing 150 - 175 grams were fasted for 24 hours with free access to water.
2. The test drugs were administered (p.o.) 45 minutes before alcohol administration.
3. 1 ml of chilled absolute alcohol was administered (p.o.) to the rats (According to the Wittetal).
4. Immediately after 1 hour, the animals were anesthetized, abdomen was cut opened stomach was taken out and incised along the greater curvature to observe the gastric lesions.
= The ulcers are examined under the 5X magnification with the help of magnascope.
Absolute ethanol lesions appears as blackish lesions grouped in patches of varying size, usually parallel to the major axis of the stomach.
5. The lengths of the lesions are measured and summated to give a total lesion score, then calculated and expressed in percentage.
The effect of HF against alcohol induced ulcer model is given in Table7. The effect of the standard drug "Omeprazole" is also given in Table 7 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against alcohol induced ulcer model are tabulated in Table 8 given at the end of the description.
INFERENCE: The composition of the present invention does not show any significant effect against alcohol induced gastric ulcer model.
EXPERIMENT 5: EFFECT ON PYLORIC LIGATION INDUCED ULCER
MODEL
Method:
1. Animals were fasted for 24 hours in the raised mesh bottom cages to prevent coprophagia and were allowed free access to water.
2. The control group of rats was feed with the vehicle and the experimental groups with their respective drugs 45 minutes prior to the ligation.
3. The animal was anesthetized, abdomen was cut opened under xiphoid process, and the pyloric portion of the stomach was slightly lifted and ligated avoiding any 5 damage to the adjacent blood vessels (According to the method of Shay et al.
1945).
4. The animals were stitched and kept for 4 hours with free access to water.
5. After 4 hours the animals were sacrificed under ether anesthesia and the stomach was dissected out incised along the greater curvature.
INFERENCE: The Herbal composition of the present invention "HF" shows significant anti ulcer effect against this model.
EXPERIMENT 4: EFFECT ON ALCOHOL INDUCED GASTRIC ULCERS IN
RATS
Method:
1. Adult rats of either sex were taken; weighing 150 - 175 grams were fasted for 24 hours with free access to water.
2. The test drugs were administered (p.o.) 45 minutes before alcohol administration.
3. 1 ml of chilled absolute alcohol was administered (p.o.) to the rats (According to the Wittetal).
4. Immediately after 1 hour, the animals were anesthetized, abdomen was cut opened stomach was taken out and incised along the greater curvature to observe the gastric lesions.
= The ulcers are examined under the 5X magnification with the help of magnascope.
Absolute ethanol lesions appears as blackish lesions grouped in patches of varying size, usually parallel to the major axis of the stomach.
5. The lengths of the lesions are measured and summated to give a total lesion score, then calculated and expressed in percentage.
The effect of HF against alcohol induced ulcer model is given in Table7. The effect of the standard drug "Omeprazole" is also given in Table 7 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against alcohol induced ulcer model are tabulated in Table 8 given at the end of the description.
INFERENCE: The composition of the present invention does not show any significant effect against alcohol induced gastric ulcer model.
EXPERIMENT 5: EFFECT ON PYLORIC LIGATION INDUCED ULCER
MODEL
Method:
1. Animals were fasted for 24 hours in the raised mesh bottom cages to prevent coprophagia and were allowed free access to water.
2. The control group of rats was feed with the vehicle and the experimental groups with their respective drugs 45 minutes prior to the ligation.
3. The animal was anesthetized, abdomen was cut opened under xiphoid process, and the pyloric portion of the stomach was slightly lifted and ligated avoiding any 5 damage to the adjacent blood vessels (According to the method of Shay et al.
1945).
4. The animals were stitched and kept for 4 hours with free access to water.
5. After 4 hours the animals were sacrificed under ether anesthesia and the stomach was dissected out incised along the greater curvature.
10 6. The stomach was washed thoroughly and the ulcer index was scored as per in other ulcer models.
The effect of HF against pyloric ligation induced ulcer is given in Table 9.
The effect of the standard drug "Omeprazole" is also given in Table 9 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against pyloric ligation induced ulcer are tabulated in Table 10 given at the end of the description.
INFERENCE: On comparison, Herbal composition shows high anti ulcer activity.
The anti ulcer activity of the herbal composition is higher than that of Omeprazole.
EXPERIMENT 6: HERBS AND PREPARATION OF THE COMPOSITION
Method:
For the purpose of conducting animal experiment all the herbs are washed dried and pulverized. All the herbs are taken in the proportion as shown in Table 11. To this water was added and boiled and concentrated to appropriate consistency. The components and their proportions of the standard "herbal composition " (HF) according to one embodiment of the present invention are listed in Tablell given at the end of the description. The parts of the herbs which can be used is also mentioned. The placebo preparation is designed to taste, smell and look like an Ayurvedic herbal formulation. .
TABLE 1: Effect of New herbal composition (HF) against Cold Restraint Ulcer Model (CRU) with Omeprazole as a standard drug.
Compound Ulcer severity_(type of lesions) Mean Percentage of Ulcer Protection and Doses Scores No. of rats showing severity ulcer incidence index index lesions / No. of rats tested) of ulcer (No. of rats 10 20 30 40 50 score showing ulcer/
total No. of rats used) Control - 6/10 4/10 -- -- 24 100 (10/10) 12.4 00 CRU
The effect of HF against pyloric ligation induced ulcer is given in Table 9.
The effect of the standard drug "Omeprazole" is also given in Table 9 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against pyloric ligation induced ulcer are tabulated in Table 10 given at the end of the description.
INFERENCE: On comparison, Herbal composition shows high anti ulcer activity.
The anti ulcer activity of the herbal composition is higher than that of Omeprazole.
EXPERIMENT 6: HERBS AND PREPARATION OF THE COMPOSITION
Method:
For the purpose of conducting animal experiment all the herbs are washed dried and pulverized. All the herbs are taken in the proportion as shown in Table 11. To this water was added and boiled and concentrated to appropriate consistency. The components and their proportions of the standard "herbal composition " (HF) according to one embodiment of the present invention are listed in Tablell given at the end of the description. The parts of the herbs which can be used is also mentioned. The placebo preparation is designed to taste, smell and look like an Ayurvedic herbal formulation. .
TABLE 1: Effect of New herbal composition (HF) against Cold Restraint Ulcer Model (CRU) with Omeprazole as a standard drug.
Compound Ulcer severity_(type of lesions) Mean Percentage of Ulcer Protection and Doses Scores No. of rats showing severity ulcer incidence index index lesions / No. of rats tested) of ulcer (No. of rats 10 20 30 40 50 score showing ulcer/
total No. of rats used) Control - 6/10 4/10 -- -- 24 100 (10/10) 12.4 00 CRU
CRU+HF 4/10 2/10 -- -- -- 08 60 (6/10) 6.8 45.16 (50mg/Kg, p..o.) CRU+Ome 3/10 2/10 -- -- -- 07 50 (5/10) 5.7 54.03 prazole (10 mg/Kg, P.O.) In the table, 10 = Shedding of epithelium; 20 = Petechial and frank hemorrhages; 30 = One or two ulcers; 40 = More than two ulcers; 50 = Perforated ulcers.
TABLE 2: Percentage protection of Herbal composition against Cold Restraint Ulcer Model (CRU) taking Omeprazole as a standard drug.
GROUP PERCENTAGE
PROTECTION
Herbal composition (HF) of the present invention (50 83.58 mg/Kg) *Omerprazole (10 mg/Kg) 100%
*The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 3: Effect of Herbal composition against Aspirin induced ulcer model with Omeprazole as a standard drug.
Compound Ulcer severity (type of Mean Percentage of ulcer Ulcer Prote and Doses lesions) Scores (No. of rats severity incidence (No. of rats index ction showing lesions / No. of rats of ulcer showing ulcer/total index tested) score No. of rats used) Control - 2/6 4/6 -- -- 26.6 100 (6/6) 12.66 00 Aspirin (150 m P.O.) Aspirin + 2/6 3/6 -- -- -- 13.3 83.3 (5/6) 9.66 23.6 Herbal 9 composition (100m /K ) Aspirin + 2/6 1/6 -- -- -- 6.6 50 (3/6) 5.66 54.8 Omeprazole 1 (20 mg/Kg) In the table, 10 = Shedding of epithelium; 20 = Petechial and frank hemorrhages; 30 = One or two ulcers; 40 = More than two ulcers; 50 = Perforated ulcers.
TABLE 4: Percentage protection of Herbal composition against aspirin induced ulcer model taking Omeprazole as a standard drug.
Compound Percentage protection Herbal composition (50 mg/Kg) 60.12 * Omeprazole (10 mg/Kg) 100 * The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 2: Percentage protection of Herbal composition against Cold Restraint Ulcer Model (CRU) taking Omeprazole as a standard drug.
GROUP PERCENTAGE
PROTECTION
Herbal composition (HF) of the present invention (50 83.58 mg/Kg) *Omerprazole (10 mg/Kg) 100%
*The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 3: Effect of Herbal composition against Aspirin induced ulcer model with Omeprazole as a standard drug.
Compound Ulcer severity (type of Mean Percentage of ulcer Ulcer Prote and Doses lesions) Scores (No. of rats severity incidence (No. of rats index ction showing lesions / No. of rats of ulcer showing ulcer/total index tested) score No. of rats used) Control - 2/6 4/6 -- -- 26.6 100 (6/6) 12.66 00 Aspirin (150 m P.O.) Aspirin + 2/6 3/6 -- -- -- 13.3 83.3 (5/6) 9.66 23.6 Herbal 9 composition (100m /K ) Aspirin + 2/6 1/6 -- -- -- 6.6 50 (3/6) 5.66 54.8 Omeprazole 1 (20 mg/Kg) In the table, 10 = Shedding of epithelium; 20 = Petechial and frank hemorrhages; 30 = One or two ulcers; 40 = More than two ulcers; 50 = Perforated ulcers.
TABLE 4: Percentage protection of Herbal composition against aspirin induced ulcer model taking Omeprazole as a standard drug.
Compound Percentage protection Herbal composition (50 mg/Kg) 60.12 * Omeprazole (10 mg/Kg) 100 * The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 5: Effect of Herbal composition against histamine induced duodenal ulcer in Guinea pig with Omeprazole as a standard drug.
Groups Ulcer severity (type of Mean Percentage of Ulcer % Volume of and lesions) Scores (No. severity ulcer incidence index Prote gastric doses of Guinea pig showing lesions of ulcer (No. of animals ction fluid (1nL) coinpou / No. Guinea pig tested) score showing nds 10 20 30 40 50 ulcer/total No. of animals used) Ulcer -- -- 1/3 2/3 -- 36.6 100 (3/3) 13.66 00 4.33 1.1 Control (Histam ine(25 mg/Kg, i.m.) Histami -- -- -- 1/3 -- 13.33 33.3(1/3) 4.66 65.88 2.7.+ 0.37 ne+HF
(50 mg/Kg., P.O.) Histami -- 1/3 -- -- -- 6.66 33.33 (1/3) 3.99 70.79 1.0 .+ 0.2 ne +
Omepra zole (10 mg/Kg, P.O.) TABLE 6: Percentage protection of Herbal composition against histamine induced duodenal ulcer in Guinea pig taking Omeprazole as a standard drug.
COMPOUND PERCENTAGE PROTECTION
Herbal composition 93.07 * Omeprazole 100 * The protection of Omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 7: Effect of Herbal composition against Ethanol Induced Ulcer Model with Omeprazole as a standard drug.
COMPOUND LENGTH OF HEMORRHAGIC
BANDS (mm SE) Ethanol Control 73.5 1.5 Herbal composition (HF) of the present 69.0 7.0 invention (1 00m /K ,p.o.) + Ethanol Omeprazole (100mg/Kg,p.o.) + Ethanol 56.0 9.12 TABLE S: Percentage protection of Herbal composition against Alcohol induced Ulcer Model taking Omeprazole as a standard drug.
COMPOUNDS PROTECTION
Herbal composition 25.71 * Omeprazole 100.0 * The protection of omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of omeprazole.
Groups Ulcer severity (type of Mean Percentage of Ulcer % Volume of and lesions) Scores (No. severity ulcer incidence index Prote gastric doses of Guinea pig showing lesions of ulcer (No. of animals ction fluid (1nL) coinpou / No. Guinea pig tested) score showing nds 10 20 30 40 50 ulcer/total No. of animals used) Ulcer -- -- 1/3 2/3 -- 36.6 100 (3/3) 13.66 00 4.33 1.1 Control (Histam ine(25 mg/Kg, i.m.) Histami -- -- -- 1/3 -- 13.33 33.3(1/3) 4.66 65.88 2.7.+ 0.37 ne+HF
(50 mg/Kg., P.O.) Histami -- 1/3 -- -- -- 6.66 33.33 (1/3) 3.99 70.79 1.0 .+ 0.2 ne +
Omepra zole (10 mg/Kg, P.O.) TABLE 6: Percentage protection of Herbal composition against histamine induced duodenal ulcer in Guinea pig taking Omeprazole as a standard drug.
COMPOUND PERCENTAGE PROTECTION
Herbal composition 93.07 * Omeprazole 100 * The protection of Omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 7: Effect of Herbal composition against Ethanol Induced Ulcer Model with Omeprazole as a standard drug.
COMPOUND LENGTH OF HEMORRHAGIC
BANDS (mm SE) Ethanol Control 73.5 1.5 Herbal composition (HF) of the present 69.0 7.0 invention (1 00m /K ,p.o.) + Ethanol Omeprazole (100mg/Kg,p.o.) + Ethanol 56.0 9.12 TABLE S: Percentage protection of Herbal composition against Alcohol induced Ulcer Model taking Omeprazole as a standard drug.
COMPOUNDS PROTECTION
Herbal composition 25.71 * Omeprazole 100.0 * The protection of omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of omeprazole.
TABLE 9: Effect of Herbal composition against pyloric ligation induced Ulcer taking Omeprazole as a Standard drug Groups Ulcer Index Protection Index Ligation Control 16.6 00 Ligation + Herbal composition (50 mg/Kg, p.o.) 4.2 65.89 Ligation + Omeprazole (10 mg/Kg, p.o.) 6.6 51.44 TABLE 10: Percentage protection of Herbal composition against pyloric ligation induced Ulcer Model taking Omeprazole as a standard drug.
COMPOUNDS PROTECTION
Herbal composition 124.0 * Omeprazole 100 * The protection of Omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 11: Composition of the Herbal composition (HF) of the present invention.
S. NO. NAME OF THE INGREDIENT (PART USED) %
1 Blechnum orintale(root) 5-6 %
2 Vitis vini era (Fruit) 5-9 %
3 Aegle marmelos(Root) 4-7 %
4 Withania somni ra(Root) 4-8 %
5 Feronia ele hantum(Fruit) 5-8 %
6 Punica rantum(Fruit) 8-10 %
7 Ziniber officnale (Rhizome) 4-8 %
8 Piper nigrum (Fruit) 2-9 %
9 Piper longum (Fruit) 8-10 %
Azadirachta indica (Barlc) 2-9 %
COMPOUNDS PROTECTION
Herbal composition 124.0 * Omeprazole 100 * The protection of Omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
TABLE 11: Composition of the Herbal composition (HF) of the present invention.
S. NO. NAME OF THE INGREDIENT (PART USED) %
1 Blechnum orintale(root) 5-6 %
2 Vitis vini era (Fruit) 5-9 %
3 Aegle marmelos(Root) 4-7 %
4 Withania somni ra(Root) 4-8 %
5 Feronia ele hantum(Fruit) 5-8 %
6 Punica rantum(Fruit) 8-10 %
7 Ziniber officnale (Rhizome) 4-8 %
8 Piper nigrum (Fruit) 2-9 %
9 Piper longum (Fruit) 8-10 %
Azadirachta indica (Barlc) 2-9 %
Claims (21)
1. A synergistic herbal composition for use in the treatment of gastric ulcer, said composition comprising an extract obtained from plant parts of Aegle marmelos and Withania somnifra, and one or more pharmaceutically acceptable additives or carriers.
2. The composition of claim 1, further comprising an extract obtained from plant parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper longum or Azadirachta indica.
3. The composition as claimed in claim 1 or 2, wherein the composition comprises 4-10% by wt. of an extract from Aegle marmelos, and 4-11% by wt. of an extract from Withania somnifra.
4. The composition of claim 2, wherein the composition comprises 4-10% by wt.
of an extract from Aegle marmelos, 4-11% by wt. of an extract from Withania somnifra, 5-8% by wt. of an extract from Blechnum orintale, 5-11 % by wt. of an extract from Vitis vinifera 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica.
of an extract from Aegle marmelos, 4-11% by wt. of an extract from Withania somnifra, 5-8% by wt. of an extract from Blechnum orintale, 5-11 % by wt. of an extract from Vitis vinifera 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica.
5. The composition as claimed in any one of claims 1 to 4, wherein the extracts are aqueous extracts.
6. The composition as claimed in any one of claims 1 to 5, wherein the plant part of Aegle marmelos and Withania somnifra is root.
7. The composition of claim 2 or 4, wherein the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
8. The composition as claimed in claim 2, 4 or 7, wherein the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit.
9. The composition as claimed in claim 2, 4, 7 or 8, wherein the plant part of Punica grantum is fruit rind.
10. The composition as claimed in claim 2, 4, 7, 8 or 9, wherein the plant part of Ziniber officnale is rbizome.
11. The composition as claimed in claim 2, 4, 7, 8, 9 or 10, wherein the plant part of Azadixachta indica is bark.
12. A process for the preparation of a synergistic herbal composition for use in the treatment of gastric ulcer, said process comprising obtaining an extract from plant parts, and forming the composition of any one of claims 1 to 11.
13. Use of an effective amount of the composition of any one of claims I to 11 for treating gastric ulcer in a subject.
14. The use according to claim 13, wherein the subject is a mammal.
15. The use according to claim 13 wherein the subject is a human.
16. The use according to claim 15, wherein the composition is for use in an amount of 50 to 100 mg of the composition per Kg of body weight to the subject.
17. The use according to claim 15 or 16, wherein the composition is in the form of a tablet, capsule, or syrup.
18. The use according to any one of claims 15 to 17, wherein the composition is formulated for oral or intra muscular use.
19. The use according to any one of claims 15 to 18, wherein the composition is for prophylactic treatment of gastric ulcer.
20. The use according to any one of claims 15 to 19, wherein the composition is for use in a single dose.
21. The use according to any one of claims 15 to 19, wherein the composition is for use in multiple doses.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2002/001122 WO2003080086A1 (en) | 2002-03-25 | 2002-03-25 | A composition for treating gastric ulcer and a process for preparing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2480223A1 CA2480223A1 (en) | 2003-10-02 |
CA2480223C true CA2480223C (en) | 2011-06-21 |
Family
ID=28053158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2480223A Expired - Fee Related CA2480223C (en) | 2002-03-25 | 2002-03-25 | A composition for treating gastric ulcer and a process for preparing the same |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1490079A1 (en) |
JP (1) | JP2005526791A (en) |
CN (1) | CN1627953A (en) |
AU (1) | AU2002247908A1 (en) |
CA (1) | CA2480223C (en) |
WO (1) | WO2003080086A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713092B1 (en) * | 2002-12-03 | 2004-03-30 | Natreon Inc. | Withania Somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof |
WO2014010658A1 (en) * | 2012-07-11 | 2014-01-16 | 興和株式会社 | Preparation containing indian long pepper |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08295632A (en) * | 1995-03-02 | 1996-11-12 | Takeda Chem Ind Ltd | Antibacterial agent |
IN188667B (en) * | 1995-06-14 | 2002-10-26 | Council Scient Ind Res | |
FR2775686B1 (en) * | 1998-03-09 | 2006-07-28 | Pascal Commenil | INDUSTRIAL AND COMMERCIAL EXPLOITATION OF CUTICULAR LIPIDS IN THE BAY OF GRAPE IN PHARMACOLOGY AND COSMETOLOGY |
US6291517B1 (en) * | 1999-11-19 | 2001-09-18 | Dry Creek Nutrition, Inc | Method for preventing or reducing stress-induced gastric injury using grape seed proanthocyanidin extract |
-
2002
- 2002-03-25 AU AU2002247908A patent/AU2002247908A1/en not_active Abandoned
- 2002-03-25 JP JP2003577912A patent/JP2005526791A/en active Pending
- 2002-03-25 CN CNA028290011A patent/CN1627953A/en active Pending
- 2002-03-25 EP EP02716987A patent/EP1490079A1/en not_active Withdrawn
- 2002-03-25 WO PCT/IB2002/001122 patent/WO2003080086A1/en active Application Filing
- 2002-03-25 CA CA2480223A patent/CA2480223C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1490079A1 (en) | 2004-12-29 |
AU2002247908A1 (en) | 2003-10-08 |
CN1627953A (en) | 2005-06-15 |
JP2005526791A (en) | 2005-09-08 |
WO2003080086A1 (en) | 2003-10-02 |
CA2480223A1 (en) | 2003-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001250634B8 (en) | An improved herbal composition having antiallergic properties and a process for the preparation thereof | |
Burli et al. | A comprehensive review on Butea monosperma (Lam.) Kuntze | |
US7438932B2 (en) | Method for treating stomach ulcers with herbal extract composition | |
Onasanwo et al. | Anti-ulcerogenic and proton pump (H+, K+ ATPase) inhibitory activity of Kolaviron from Garcinia kola Heckel in rodents | |
AU749922B2 (en) | A medicament for treating recurrent ulcer of mouth and Behcet's syndrome | |
US6365198B1 (en) | Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids | |
JP2535559B2 (en) | Agent for the prevention and treatment of pruritus in fish | |
Sharma et al. | Ethnopharmacological importance of Asparagus racemosus: A review | |
CA2480223C (en) | A composition for treating gastric ulcer and a process for preparing the same | |
US6855347B2 (en) | Composition for treating gastric ulcer and a process for preparing the same | |
JP2535555B2 (en) | Agent for preventing and treating streptococcal disease in fish | |
JP2599160B2 (en) | Preventive and therapeutic agent for staphylococcal disease in chickens | |
US20120121736A1 (en) | Composition for treating gastric ulcer and a process thereof | |
US7651705B2 (en) | Herbal composition for the treatment of gastric ulcer | |
Khan | Effect of Unani Formulations on Frostbite Induced Gangrene–A Case Report | |
JP2599154B2 (en) | Agent for prevention and treatment of haemophilus infection in pigs | |
RU2302255C2 (en) | Anti-ulcerous plant composition, method for its obtaining and application | |
Van Anh et al. | 9. Gastroprotective effect of Vien Khoi Tim capsules on indomethacin-induced gastric ulcers in rats | |
Hossain et al. | 1Hamdard Unani Medical College & Hospital, Bogra, Bangladesh 2Hakim Said Eastern Medical College & Hospital, 37 Nobab Katara (Nimtoli), Dhaka-1000, Bangladesh Corresponding author: Md. Tofazzal Hossain, Hamdard Unani Medical College & Hospital, Bogra, Bangladesh. E-mail: drtofazzalbd@ gmail. com | |
Mohammad et al. | THE ANTI-ULCEROGENIC ACTIVITY OF THE CRUDE METHANOLIC EXTRACT OF MONECHMA CILIATUM SEEDS | |
Ross | Punica granatum | |
CN105267928A (en) | Pharmaceutical composition for treating peptic ulcer | |
CN105267828A (en) | Solid dispersion for treating peptic ulcer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150325 |